Vivos Therapeutics (VVOS) Cash from Investing Activities (2020 - 2026)
Vivos Therapeutics' (VVOS) quarterly Cash from Investing Activities came in at -$18000.0 in Q1 2026, up 85.25% year-on-year from -$9716.8 in Q1 2025, and up 98.86% on a QoQ basis from -$1.6 million in Q4 2025.
Vivos Therapeutics (VVOS) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Vivos Therapeutics (VVOS) has 7 years of Cash from Investing Activities data on file, last reported at -$18000.0 in Q1 2026.
- On a quarterly basis, Cash from Investing Activities rose 85.25% year-over-year to -$18000.0 in Q1 2026; TTM through Mar 2026 was -$7.4 million, a 1276.99% decrease from a year earlier, with the FY2025 full-year figure at -$7.5 million, down 1225.0% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$18000.0, up from -$1.6 million in the prior quarter.
- Over the last five years, Cash from Investing Activities for VVOS reached as high as $83000.0 in Q3 2025 and fell as low as -$5.9 million in Q2 2025.
- Historically, Cash from Investing Activities has averaged -$581705.9 across 5 years, with a median of -$165000.0 in 2023.
- On a YoY basis, Cash from Investing Activities climbed as much as 143.23% in 2025 and fell as far as 9743.33% in 2025.
- Year by year, Cash from Investing Activities stood at -$200000.0 in 2022, then rose by 17.5% to -$165000.0 in 2023, then changed by 0.0% to -$165000.0 in 2024, then sank by 858.18% to -$1.6 million in 2025, then surged by 98.86% to -$18000.0 in 2026.
- Per Business Quant data, the three most recent Cash from Investing Activities figures were -$18000.0 in Q1 2026, -$1.6 million in Q4 2025, and $83000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.88 Bn | 176.59 Bn | 6.27 Bn | -20.32 Bn |
| 2 | Stryker | 128.94 Bn | 126.06 Bn | 3.81 Bn | -185.00 Mn |
| 3 | Medtronic | 108.75 Bn | 99.53 Bn | 6.41 Bn | -917.00 Mn |
| 4 | Boston Scientific | 68.65 Bn | 67.19 Bn | 3.61 Bn | -591.00 Mn |
| 5 | Edwards Lifesciences | 48.22 Bn | 44.55 Bn | 1.29 Bn | -92.80 Mn |
| 6 | Dexcom | 28.43 Bn | 27.31 Bn | 750.30 Mn | -298.50 Mn |
| 7 | GE HealthCare Technologies | 28.32 Bn | 26.03 Bn | 1.98 Bn | -2.50 Bn |
| 8 | Smith & Nephew | 26.91 Bn | 26.33 Bn | - | - |
| 9 | Koninklijke Philips | 25.10 Bn | 21.98 Bn | 2.07 Bn | -475.32 Mn |
| 10 | Vivos Therapeutics | 5.71 Mn | 3.60 Mn | 3.06 Mn | -18,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18,000.00 |
| Mar 31, 2026 | -18,000.00 |
| Dec 31, 2025 | -1.58 Mn |
| Dec 31, 2025 | -1.58 Mn |
| Sep 30, 2025 | 83,000.00 |
| Sep 30, 2025 | 83,000.00 |
| Jun 30, 2025 | -5.91 Mn |
| Jun 30, 2025 | -5.91 Mn |
| Mar 31, 2025 | -122,000.00 |
| Mar 31, 2025 | -122,000.00 |
| Dec 31, 2024 | -165,000.00 |
| Dec 31, 2024 | -165,000.00 |
| Sep 30, 2024 | -192,000.00 |
| Sep 30, 2024 | -192,000.00 |
| Jun 30, 2024 | -60,000.00 |
| Jun 30, 2024 | -60,000.00 |
| Mar 31, 2024 | -151,000.00 |
| Mar 31, 2024 | -151,000.00 |
| Dec 31, 2023 | -165,000.00 |
| Dec 31, 2023 | -165,000.00 |